Abstract
The aims of the Research Institute for Fragrance Materials, Inc. (RIFM), an international nonprofit science-based organization established in 1966 by the fragrance industry, include the prevention of adverse cutaneous effects, systemic toxicity, and environmental consequences from fragrance ingredients. This paper gives an overview of the RIFM testing and research program, how priorities are established, and how RIFM's safety evaluation process works.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 100-103 |
| Number of pages | 4 |
| Journal | American Journal of Contact Dermatitis |
| Volume | 14 |
| Issue number | 2 |
| State | Published - Jun 2003 |
Fingerprint
ASJC Scopus subject areas
- Dermatology
Cite this
Considerations for testing irritancy, allergy, and photoreactivity in fragrance safety evaluations. / Hanifin, Jon; Api, Anne Marie; Bickers, David R.
In: American Journal of Contact Dermatitis, Vol. 14, No. 2, 06.2003, p. 100-103.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Considerations for testing irritancy, allergy, and photoreactivity in fragrance safety evaluations
AU - Hanifin, Jon
AU - Api, Anne Marie
AU - Bickers, David R.
PY - 2003/6
Y1 - 2003/6
N2 - The aims of the Research Institute for Fragrance Materials, Inc. (RIFM), an international nonprofit science-based organization established in 1966 by the fragrance industry, include the prevention of adverse cutaneous effects, systemic toxicity, and environmental consequences from fragrance ingredients. This paper gives an overview of the RIFM testing and research program, how priorities are established, and how RIFM's safety evaluation process works.
AB - The aims of the Research Institute for Fragrance Materials, Inc. (RIFM), an international nonprofit science-based organization established in 1966 by the fragrance industry, include the prevention of adverse cutaneous effects, systemic toxicity, and environmental consequences from fragrance ingredients. This paper gives an overview of the RIFM testing and research program, how priorities are established, and how RIFM's safety evaluation process works.
UR - http://www.scopus.com/inward/record.url?scp=0043234638&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0043234638&partnerID=8YFLogxK
M3 - Article
VL - 14
SP - 100
EP - 103
JO - Dermatitis : contact, atopic, occupational, drug
JF - Dermatitis : contact, atopic, occupational, drug
SN - 1710-3568
IS - 2
ER -